Relmada Therapeutics, Inc. balance sheet RLMD

Annual Quarterly

As of Jun 30, 2026, Relmada Therapeutics, Inc. had total assets of $219.1 million and total liabilities of $12.5 million. Total assets were up 937.4% from a year earlier. Stockholders' equity was $206.6 million. Cash and investments were $217.7 million. The current ratio, current assets divided by current liabilities, was 29.52.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2019
Jun 30, 2019
FY 2018
Jun 30, 2018
FY 2017
Jun 30, 2017
Assets
Cash
11
+737.5%
3
-9.3%
4
-5.7%
4
-24.2%
5
—
2
-72.9%
36
+1520.3%
9
+311.6%
2
+30.9%
2
-79.9%
Short-term investments
206
+971.3%
90
+118.0%
41
-55.5%
92
-35.5%
143
-14.7%
167
+46.1%
115
+42.9%
80
—
—
—
Cash and investments
218
+955.9%
93
+107.1%
45
-53.4%
96
-35.1%
148
-11.4%
167
+43.0%
117
+31.0%
116
+5100.8%
9
+311.6%
2
+30.9%
2
-79.9%
Receivables
—
—
—
—
1
—
—
—
—
—
—
Total current assets
219
+938.4%
94
+105.2%
46
-53.0%
98
-36.2%
153
-31.5%
223
+89.1%
118
+1082.6%
117
+4171.1%
10
+264.7%
3
+10.6%
2
-73.4%
Property and equipment, net
—
—
—
—
—
—
0
-82.6%
0
-58.5%
0
-40.3%
0
+421.8%
0
-99.6%
Total assets
219
+937.4%
94
+105.2%
46
-53.0%
98
-36.2%
153
-31.5%
223
+89.0%
118
+1056.5%
117
+3742.9%
10
+235.3%
3
+7.4%
3
-72.3%
Liabilities and equity
Accounts payable
2
+76.9%
2
-62.0%
4
+17.8%
4
-33.4%
5
-53.0%
11
+34.1%
8
+802.9%
1
-31.7%
1
+20.8%
1
+44.5%
1
-58.0%
Total current liabilities
7
+44.5%
6
-37.5%
10
-15.6%
12
-2.2%
12
-17.2%
15
+19.5%
13
+383.6%
1
-75.3%
3
-55.9%
6
+328.9%
1
-55.0%
Total liabilities
13
+142.0%
7
-27.2%
10
-15.6%
12
-2.2%
12
-17.2%
15
+19.5%
13
+383.6%
1
-83.0%
3
-69.6%
9
+521.9%
1
-57.0%
Stockholders' equity
207
+1195.1%
87
+143.5%
36
-58.4%
85
-39.2%
140
-32.6%
208
+97.3%
106
+1286.8%
116
+2198.3%
8
+238.1%
-6
-477.5%
1
-79.3%
Ratios
Current ratio
29.52x
14.62x
4.45x
8.00x
12.26x
14.83x
9.37x
80.21x
3.83x
0.46x
1.80x
Return on equity
-29.98%
-66.33%
-225.15%
-115.74%
-111.83%
-60.38%
-56.31%
-14.97%
-227.47%
—
-430.50%
Return on assets
-28.27%
-61.05%
-174.56%
-101.27%
-102.71%
-56.31%
-50.31%
-14.78%
-169.46%
-293.98%
-221.60%
Book value per share
1.94
1.18
1.18
2.84
4.67
7.51
6.46
8.00
0.78
-1.76
0.12
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RLMD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Coral Gables, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1553643
Former names
CAMP NINE, INC. (until Jul 14, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.